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Abstract
Aims/hypothesis Intensive glucose control reduces the risk of
vascular complications while increasing the risk of severe
hypoglycaemia at a group level. We sought to estimate indi-
vidual beneficial and adverse effects of intensive glucose con-
trol in patients with type 2 diabetes.
Methods We performed a post hoc analysis of the Action in
Diabetes and Vascular Disease: Preterax and Diamicron MR
Controlled Evaluation (ADVANCE) trial, a randomised con-
trolled trial evaluating standard vs intensive glucose control
(HbA1c target ≤6.5% [48 mmol/mol]). In 11,140 participants,
we estimated the individual 5 year absolute risk reduction
(ARR) for the composite outcome of major micro- and
macrovascular events and absolute risk increase (ARI) for
severe hypoglycaemia for intensive vs standard glucose con-
trol. Predictions were based on competing risks models
including clinical characteristics and randomised treatment.
Results Based on these models, 76% of patients had a sub-
stantial estimated 5 year ARR for major vascular events (>1%,
5 year number-needed-to-benefit [NNTB5] <100) and 1% had
a small ARR (<0.5%, NNTB5 >200). Similarly, 36% of
patients had a substantial estimated ARI for severe
hypoglycaemia (5 year number-needed-to-harm [NNTH5]
<100) and 29% had a small ARI (NNTH5 >200). When
assigning similar or half the weight to severe hypoglycaemia
compared with a major vascular event, net benefit was posi-
tive in 85% or 99% of patients, respectively. Limiting inten-
sive treatment to the 85% patient subgroup had no significant
effect on the overall incidence of major vascular events and
severe hypoglycaemia compared with treating all patients.
Conclusions/interpretation Taking account of the effects of
intensive glucose control on major micro- and macrovascular
events and severe hypoglycaemia for individual patients, the
estimated net benefit was positive in the majority of the par-
ticipants in the ADVANCE trial. The estimated individual
effects can inform treatment decisions once individual weights
assigned to positive and adverse effects have been specified.
Trial registration: ClinicalTrials.gov NCT00145925
Electronic supplementary material The online version of this article
(doi:10.1007/s00125-016-4082-5) contains peer-reviewed but unedited
supplementary material, which is available to authorised users.
* Frank L. J. Visseren
f.l.j.visseren@umcutrecht.nl
1 Department of Vascular Medicine, University Medical Centre
Utrecht, PO Box 85500, 3508 GA Utrecht, the Netherlands
2 The George Institute for Global Health, University of Sydney,
Sydney, NSW, Australia
3 The George Institute for Global Health, Nuffield Department of
Population Health, University of Oxford, Oxford, UK
4 Julius Centre for Health Sciences and Primary Care, University
Medical Centre Utrecht, Utrecht, the Netherlands
5 The Royal Melbourne Hospital, University of Melbourne,
Melbourne, VIC, Australia
6 University of Sheffield and Sheffield Teaching Hospitals NHS
Foundation Trust, Sheffield, UK
7 Istituto Auxologico Italiano, University of Milano-Bicocca,
Milan, Italy
8 Hôpital Bichat-Claude Bernard and Université Paris 7, Paris, France
9 International Centre for Circulatory Health, Imperial College,
London, UK
Diabetologia (2016) 59:2603–2612
DOI 10.1007/s00125-016-4082-5
Keywords Glycaemic target . Hypoglycaemia . Net benefit .
Personalised medicine . Type 2 diabetes . Vascular
complications
Abbreviations
ADVANCE Action in Diabetes and Vascular Disease:
Preterax and Diamicron MR Controlled
Evaluation
ACCORD Action to Control Cardiovascular Risk in
Diabetes
ARI Absolute risk increase
ARR Absolute risk reduction
CKD-EPI Chronic Kidney Disease Epidemiology
Collaboration
eGFR Estimated GFR
EME Established market economies
NNTB5 5 year number-needed-to-benefit
NNTH5 5 year number-needed-to-harm
UACR Urinary albumin/creatinine ratio
Introduction
Type 2 diabetes mellitus is a growing worldwide health prob-
lem, with 592 million people predicted to be living with dia-
betes by 2035 [1]. Observational studies have shown a close
relationship between hyperglycaemia and the risk of vascular
complications [2–4]. Subsequently, randomised trials have
demonstrated beneficial effects of intensive glucose control
on the incidence of microvascular diseases, such as retinopa-
thy and nephropathy [5, 6]. The reduction in risk of
macrovascular events has been modest in the short and medi-
um term and may take more time to accrue [7–9]. However,
intensive glucose control is also associated with disadvan-
tages, such as an approximately doubled risk of severe
hypoglycaemia depending on the glucose-lowering treatment
being received [6, 10]. Severe hypoglycaemia is, in turn, as-
sociated with a nearly threefold increased risk of premature
death, although this association may not be causal [11].
The increased risk of death with intensive glucose control
observed in the Action to Control Cardiovascular Risk in
Diabetes (ACCORD) trial has fuelled debate about whom to
treat and what glycaemic target to use [12]. Current guidelines
recommend a patient-centred approach, with consideration of
the patient’s risk of hypoglycaemia, but offer few tools to
identify patients for whom a stricter glycaemic target is likely
to be worthwhile [13, 14]. Indeed, individual patients will
have different chances to benefit from treatment and, similarly,
a varied risk of experiencing the negative effects of treatment.
For example, the anticipated risk reduction of vascular com-
plications by intensive glucose control for individual patients
depends on the estimated risk of vascular events [15].
Similarly, the susceptibility to severe hypoglycaemia is vari-
able and patients will be affected by treatment differently [11].
Further, the appraisal of the potential short-term negative ef-
fects and long-term beneficial vascular effects of treatment will
vary between patients. Thus, for some individuals the disad-
vantages of targeting near normal glucose levels might offset
treatment benefits [16, 17].
In the present study, we aimed to estimate the beneficial
and adverse effects of intensive glucose management, in terms
of risk reduction for major vascular events and risk increase
for severe hypoglycaemia, for individual patients with type 2
diabetes from the ADVANCE trial.
Methods
The design, rationale and outcomes of the ADVANCE trial
have been described elsewhere [18, 19]. Briefly, the trial was a
factorial randomised controlled trial that evaluated the effect
of intensive glucose control and BP lowering in individuals
diagnosed with type 2 diabetes, aged ≥55 years, from 215
collaborating centres in 20 countries in Asia, Australasia,
Europe and North America. Eligible individuals had a history
of micro- or macrovascular disease, or at least one risk factor
for vascular disease. There were no HbA1c or BP criteria for
inclusion. Intensive glucose control was defined as the use of
gliclazide (modified release) plus other drugs, as required, to
achieve an HbA1c value of ≤6.5% (48 mmol/mol). The target
HbA1c value for standard glucose control was defined by local
guidelines.
The endpoints considered in the current study were major
vascular events (the original primary outcome comprising
major micro- and macrovascular events) and severe
hypoglycaemia. Macrovascular events included death from
cardiovascular causes, myocardial infarction or stroke.
Microvascular events included new or worsening nephropa-
thy (i.e. development of macroalbuminuria [defined as urinary
albumin/creatinine ratio (UACR) >300 μg/mg or doubling of
serum creatinine to ≥200 mmol/l], the need for renal replace-
ment therapy or death due to renal disease) or retinopathy (i.e.
development of proliferative retinopathy, macular oedema or
diabetes-related blindness, or the use of retinal photocoagula-
tion therapy).
Hypoglycaemia was defined as a plasma glucose level of
<2.8 mmol/l or the presence of typical symptoms and signs of
hypoglycaemia without another apparent cause. Patients with
transient dysfunction of the central nervous system who
required help from another person were considered to have
severe hypoglycaemia. An independent endpoint adjudication
committee, unaware of the group assignments, reviewed
source documentation for all suspected primary endpoints
and deaths.
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Data weremissing in 4.5% of participants for UACR and in
<1% for all other variables. Missing data were imputed by
single imputation methods using predictive mean matching
[20]. Approval for the trial was obtained from the institutional
ethics committee of each centre and all participants provided
written informed consent.
Model derivationWe developed two Fine and Gray compet-
ing risks models for the prediction of major vascular events
and severe hypoglycaemia based on the same set of demo-
graphic and clinical characteristics together with treatment
status (standard vs intensive treatment) [21]. Death was con-
sidered as a competing event. The pre-specified predictors at
baseline were: sex, age, diabetes duration, untreated and treat-
ed systolic BP, randomised BP-lowering treatment allocation,
current smoking, HbA1c, non-HDL-cholesterol, waist circum-
ference, UACR, estimated GFR (eGFR), history of
macrovascular disease, history of microvascular disease, geo-
graphical region, educational attainment and treatment status.
eGFR was calculated by the Chronic Kidney Disease
Epidemiology Collaboration (CKD-EPI) equation [22].
Participants were classified into three regions of origin:
established market economies (EME; reference category),
Asia and Eastern Europe [23]. Educational attainment was
defined according to age at completion of the highest level
of formal education and categorised as less (age ≤15 years,
approximately corresponding to age of completion of junior
high school education in most regions) or more (age
≥16 years). Restricted cubic splines were used to assess the
linearity assumption for continuous predictors [24, 25]. As a
result, eGFR was included both as a linear and squared term
and UACR was natural log transformed [26]. Potential interac-
tions between treatment and estimated risk, and between treat-
ment and baseline HbA1c levels were considered for each out-
come and included if the conditional likelihood ratio p value
was <0.05.
The final models were used to calculate the risk of major
vascular events and severe hypoglycaemia, with and without
treatment, for every participant by fixing the treatment vari-
able to standard and intensive treatment, respectively. The
difference was the individual patient’s 5 year absolute risk
reduction or increase (ARR or ARI), also expressed as 5 year
number-needed-to-treat for one additional patient to benefit
(NNTB5) or be harmed (NNTH5) [27]. A 5 year risk differ-
ence of >1% was considered substantial and a risk difference
of <0.5% was considered small in this study. The model was
fitted for the prediction of 5 year (median follow-up) risk.
Given the potential for an excess risk of deathwithin 5 years
with intensive glucose control [12], we repeated our analyses
for an alternative outcome: the risk of death from any cause.
Treatment interactions with HbA1c and estimated mortality
risk, as a proxy for patient frailty, were also considered.
Assessment of model performance and internal validation
Calibration was assessed by plotting the observed 5 year cumu-
lative incidence against the average predicted 5 year event risk
within groups defined by the deciles of predicted risk.
Discrimination was assessed at 5 years by the c-statistic
accounting for right censoring [28]. Further, we assessed the
amount of over-optimism by 100-fold bootstrap resampling to
derive a shrinkage factor to uniformly shrink the model coeffi-
cients and to obtain an optimism-corrected c-statistic [24, 25].
Distribution of individual treatment effect and net benefit
The distributions of estimated individual patient 5 year
ARR of major vascular events and 5 year ARI of severe
hypoglycaemia were displayed in histograms. Net benefit
was calculated as the difference between ARR and ARI
for individual patients when assuming either half or sim-
ilar weight for severe hypoglycaemia. Subsequently, we
ranked patients based on their predicted net benefit from
largest to smallest and showed the overall effect of
treating a gradually increasing proportion of patients on
the incidence of major vascular events and severe
hypoglycaemia.
Further, we evaluated whether selective treatment strate-
gies based on predicted treatment effects could result in a more
favourable trade-off between the reduction of major vascular
events, increase in severe hypoglycaemia and number of pa-
tients treated, compared with treating everyone (treating none
was not considered to be clinically acceptable). Therefore,
based on the prediction algorithms, we selectively collected
patients with an estimated positive net effect from the inter-
vention group and patients with a null or negative net benefit
from the control group. Incidence rates in these newly assem-
bled artificial populations were compared with incidence rates
in the intensive glucose control arm (the reference popula-
tion). Statistical analyses were conducted in R, version 3.1.1
(R Development Core Team, Vienna, Austria).
Results
Model derivation and performance The baseline character-
istics of the ADVANCE participants are shown in Table 1 and
the use of glucose-lowering drugs in the electronic supple-
mentary material (ESM) Table 1. During a median follow-up
of 5.0 years, 2125 major micro- and macrovascular events and
399 non-cardiovascular deaths occurred. From these data a
risk prediction algorithm for adverse events was produced
(Table 2). Interactions between intensive treatment and the
estimated risk of major vascular events and HbA1c level were
not significant (p>0.6). The risk score showed good calibra-
tion (Fig. 1a) and moderate discrimination (optimism-adjusted
c-statistic=0.68 [95% CI 0.67, 0.70]).
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During follow-up, 231 first severe hypoglycaemia episodes
occurred. The risk prediction algorithm for severe
hypoglycaemia is shown in Table 3. The interaction be-
tween treatment and the estimated risk of hypoglycaemia
was not significant (p= 0.8). By contrast, the interaction
with baseline HbA1c indicated significantly higher risks of
hypoglycaemia across increasing levels of HbA1c only in
those assigned to intensive glucose control (p = 0.048)
(Fig. 2). Model calibration (Fig. 1b) was good and dis-
crimination was moderate (optimism-adjusted c-statistic
0.68 [95% CI 0.62, 0.74]).
A complementary model for risk of death was developed
based on 1031 deaths from any cause that occurred during
follow-up (ESM Table 2). Treatment interactions with estimat-
ed risk and HbA1c were not significant (p>0.3). The risk score
showed good calibration (ESM Fig. 1) and moderate discrimi-
nation (optimism-adjusted c-statistic 0.72 [95%CI 0.71, 0.75]).
Distribution of treatment effects The overall 5 year ARR for
major vascular events was 1.3% (NNTB5=74) and the
overall ARI for severe hypoglycaemia was 1.1%
(NNTH5=87). Using the individual prediction algo-
rithms, the estimated treatment effect on major vascular
events and severe hypoglycaemia was calculated for
each participant (see Text box for an example). In
ADVANCE, 76% of participants had a substantial esti-
mated 5 year ARR for major vascular events due to
treatment (NNTB5 <100) and 1% of participants had a
small ARR (NNTB5 >200). The proportion of patients
with an intermediate ARR (NNTB5 100–200) was 23%
(Fig. 3a). With respect to the effect of intensive glucose
control on severe hypoglycaemia, 36% of participants
had a substantial predicted ARI (NNTH5 <100), where-
as 29% had a small predicted ARI (NNTH5 >200). The
proportion of patients with an intermediate ARI for se-
vere hypoglycaemia (NNTH5 100–200) was 35%
(Fig. 3b).
Altogether, 99% (Fig. 3c) or 85% (Fig. 3d) of patients
had a positive net benefit of treatment when assigning
half or similar weight to severe hypoglycaemia compared
with major vascular events, respectively. Assigning less
than half the weight to severe hypoglycaemia resulted in
a net positive effect for all participants. The characteris-
tics of patients with net positive and negative treatment
effects are summarised in ESM Table 3. In addition, the
predicted absolute risk of death was lower with intensive
treatment in all participants, irrespective of their estimat-
ed mortality risk or HbA1c level.
Group-level effects and clinical implications The overall
effect of treating a proportion of patients ranked according to
net benefit is shown in Fig. 4. Increasing the proportion of
patients treated resulted in a lower incidence of major vascular
events and higher incidence of severe hypoglycaemia. The
observed overall effects of selective prediction-based treat-
ment strategies are shown in Fig. 5. The selective strategy
encompassed intensive treatment of 85% of patients with a
predicted positive net benefit and standard glucose control
for the 15% of patients with a predicted negative net benefit.
This strategy was associated with a small non-significant
Table 1 Baseline characteristics of the ADVANCE trial population
Characteristic Total population
(N= 11,140)
Female, n (%) 4733 (42)
Age (years)a 66 ± 6
Duration of diabetes (years)a 8 ± 6
History of microvascular disease, n (%) 1155 (10)
History of macrovascular disease, n (%) 3590 (32)
Region
EME, n (%) 4862 (44)
Eastern Europe, n (%) 2142 (19)
Asia, n (%) 4136 (37)
Blood glucose control
Fasting blood glucose (mmol/l)a 8.5 ± 2.8
Serum HbA1c concentration (%)
a 7.5 ± 1.6
Serum HbA1c concentration (mmol/mol)
a 58 ± 18
Other risk factors
Systolic BP (mmHg)a 145 ± 22
Diastolic BP (mmHg)a 81 ± 11
History of treated hypertension, n (%) 7655 (69)
Non-HDL-cholesterol (mmol/l)a 3.9 ± 1.1
Triacylglycerol (mmol/l)b 1.6 (1.2–2.3)
UACR (mg/mmol)b 1.7 (0.8–4.5)
eGFR (ml/min/1.73 m2)b 75 (62–89)
Current smoking, n (%) 1682 (15)
Waist circumference (cm)a 99 ± 13
Educational attainmentc, n (%) 7121 (64)
Data is presented as %, amean ± SD or bmedian with interquartile range
cAge ≥16 years at completion
Estimated 5 year ARR for major vascular events and
ARI for severe hypoglycaemia with intensive glucose
control for a specific ADVANCE participant
A 62-year-old male patient from an EME country with a
7 year history of diabetes who has macrovascular disease,
an HbA1c of 6.7% (50 mmol/mol), a treated BP of
158/93 mmHg, a non-HDL-cholesterol level of 3.8 mmol/l,
an eGFR of 79 ml/min and a UACR of 4.8 mg/mmol:
• 5 year ARR for major vascular events=2.0%
(individual NNTB5=49)
• 5 year ARI for severe hypoglycaemia=0.5%
(individual NNTH5=196)
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increase of 0.3% (95% CI −3.7%, 4.3%) in the incidence of
major vascular events compared with treating everyone. The
incidence of severe hypoglycaemia simultaneously decreased
non-significantly by 0.5% (95% CI −1.4%, 2.4%).
Discussion
The present analysis using the ADVANCE trial demonstrates
that patient-specific characteristics at baseline can be used to
Table 2 Details of the Fine and
Gray competing risks proportion-
al hazards model for the estima-
tion of major vascular events
Variable Coefficienta sHR 95% CI p value
Glucose treatment allocation (intensive vs standard) −0.0992 0.90 0.83,0.98 0.021
Sex (women vs men) −0.3548 0.70 0.63, 0.77 <0.001
Age (per 1 year) 0.0099 1.01 1.00, 1.02 0.009
Duration of diabetes (per 1 year) 0.0279 1.03 1.02, 1.04 <0.001
Systolic BP if untreated (per 1 mmHg) 0.0039 1.00 1.00, 1.01 0.000
Systolic BP if treated (per 1 mmHg) 0.0050 1.01 1.00, 1.01 <0.001
Non-HDL-cholesterol (per 1 mmol/l) 0.0429 1.04 1.01, 1.08 0.022
HbA1c (per 1%) 0.1189 1.13 1.10, 1.16 <0.001
UACR (per 1 mg/mmol loge) 0.1625 1.18 1.14, 1.22 <0.001
eGFR (per 1 ml/min increase) −0.0255 0.97 0.96, 0.99 <0.001
eGFR squared (per 1 ml/min2) 0.0001 1.00 1.00, 1.00 0.010
Waist circumference (per 1 cm) −0.0003 1.00 1.00, 1.00 0.880
Smoking (current vs never or former) 0.0032 1.00 0.88, 1.14 0.960
History of microvascular disease (yes vs no) 0.4738 1.62 1.42, 1.86 <0.001
History of macrovascular disease (yes vs no) 0.3180 1.38 1.26, 1.51 <0.001
Educational attainment (≥16 years at completion of education) −0.2309 0.79 0.72, 0.87 <0.001
Region
Eastern Europe 0.0344 1.04 0.90, 1.19 0.610
Asia 0.2879 1.34 1.19, 1.51 <0.001
BP treatment allocation (perindopril/indapamide vs placebo) −0.0822 0.92 0.84, 1.00 0.056
5 year major vascular event risk (%) = (1− S0(5)exp(A-1.6641) ) × 100%. Where S0(5) = 0.8363 (the 5 year baseline
survival) and A is the sum, over all variables in the model, of the patient’s specific value × the corresponding
coefficient
aCoefficients were penalised by a shrinkage factor of 0.979 to increase external validity, whereas unbiased HRs
and statistics were derived from an unpenalised Fine and Gray model
To convert values for HbA1c in % to mmol/mol, subtract 2.15 and multiply by 10.929
sHR, subdistribution hazard ratio
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Fig. 1 Calibration plots. Predicted vs observed 5 year risk of (a) major vascular events and (b) severe hypoglycaemia in ADVANCE participants
(N = 11,140). Data is presented as mean ± 95% CI
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quantify the anticipated individual effects of intensive vs stan-
dard glucose control in terms of risk reduction for major
vascular events and risk increase for severe hypoglycaemia.
The estimated net benefit was positive in the majority of pa-
tients, depending upon the individual weight assigned to the
beneficial and adverse effects of treatment.
The ADVANCE trial was designed to evaluate the efficacy
of gliclazide-based intensive glucose control in a broad sample
of patients with type 2 diabetes. The strategy of intensive treat-
ment yielded an overall 10% relative risk reduction of the pri-
mary composite outcome of major micro- and macrovascular
events. The effect was largely driven by a reduction in renal
events by 21%, whereas the reduction in major cardiovascular
events was only 6% [29]. However, meta-analyses substantiate
the claim that intensive glucose control provides modest but
significant protection from macrovascular disease [7, 8]. At
the same time, intensive glucose control in ADVANCE was
associated with a more than doubled risk of severe
hypoglycaemia, although the average incidence was lower
compared with similar trials [6]. A recent Cochrane review
summarised absolute effects of intensive treatment and showed
that the average NNTB5 ranged from 32 to 142 for
microalbuminuria and from 117 to 150 for myocardial infarc-
tion. In addition, the average NNTH5 ranged from 15 to 52 for
intensive glucose control [6]. However, these estimates of ben-
eficial and harmful effects are the averages for entire study
Table 3 Details of the Fine and Gray competing risks proportional hazards model for the estimation of severe hypoglycaemia
Variable Coefficienta sHR 95% CI p value
Glucose treatment allocation (intensive vs standard)b −0.6808 0.46 0.12, 1.87 0.280
Sex (women vs men) 0.0661 1.08 0.80, 1.45 0.630
Age (per 1 year) 0.0242 1.03 1.01, 1.05 0.016
Duration of diabetes (per 1 year) 0.0278 1.03 1.01, 1.05 0.002
Systolic BP if untreated (per 1 mmHg) 0.0021 1.00 1.00, 1.01 0.520
Systolic BP if treated (per 1 mmHg) 0.0015 1.00 0.99, 1.01 0.630
Non-HDL-cholesterol (per 1 mmol/l) −0.0620 0.93 0.82, 1.06 0.290
HbA1c (per 1%) −0.0566 0.94 0.79, 1.11 0.450
HbA1c by treatment (add if on intensive treatment, per 1%)
b 0.1622 1.20 1.00, 1.44 0.048
UACR (per 1 mg/mmol loge) −0.0089 0.99 0.90, 1.09 0.830
eGFR (per 1 ml/min increase) −0.0247 0.97 0.94, 1.01 0.097
eGFR squared (per 1 ml/min2) 0.0001 1.00 1.00, 1.00 0.520
Waist circumference (per 1 cm) −0.0130 0.99 0.97, 1.00 0.031
Smoking (current vs never or former) 0.1764 1.22 0.83, 1.80 0.310
History of microvascular disease (yes vs no) 0.6043 1.98 1.38, 2.84 <0.001
History of macrovascular disease (yes vs no) 0.1775 1.22 0.92, 1.61 0.160
Educational attainment (≥16 years at completion of education) −0.3064 0.71 0.54, 0.93 0.014
Region
Eastern Europe −0.6643 0.47 0.29, 0.77 0.003
Asia −0.0592 0.94 0.66, 1.33 0.710
BP treatment allocation (perindopril/indapamide vs placebo) 0.1955 1.25 0.96, 1.62 0.098
5 year severe hypoglycaemia risk (%) = (1−S0(5)exp(A+1.1537) ) × 100%. Where S0(5) = 0.9845 (the 5 year baseline survival) and A is the sum, over all
variables in the model, of the patient’s specific value × the corresponding coefficient
aCoefficients were penalised by a shrinkage factor of 0.886 to increase external validity, whereas unbiased HRs and statistics were derived from an
unpenalised Fine and Gray model
bNeeds to be combined with the interaction term to estimate effect of intensive glucose control at specific HbA1c value (e.g. coefficient = −0.6808+
HbA1c (%) × 0.1622)
To convert values for HbA1c in % to mmol/mol, subtract 2.15 and multiply by 10.929
sHR, subdistribution hazard ratio
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Fig. 2 Graphical representation of the interaction between glucose-low-
ering treatment and baseline HbA1c on the risk of severe hypoglycaemia.
HbA1c is expressed continuously on the x-axis. The y-axis shows the risk
of severe hypoglycaemia under standard and intensive glucose control
relative to a person with an HbA1c of 7.5% (the mean) on standard glu-
cose control. To convert values for HbA1c in % to mmol/mol, subtract
2.15 and multiply by 10.929. Solid line, standard glucose control with
95% CI; dashed line, intensive glucose control with 95% CI
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populations and are not informative of the treatment effect for
individual patients [15]. Therefore, the latest joint statement
from the ADA/EASD stressed the importance of a patient-
centred approach including the consideration of diabetes dura-
tion, history of macrovascular disease and the individual’s
hypoglycaemia risk [30]. The present study aimed to provide
further details on the potential benefits and harms of treatment
intensification for individual patients.
We show that prediction models based on multiple charac-
teristics can quantify the estimated beneficial effects on major
vascular events and adverse effects on severe hypoglycaemia of
a gliclazide-based regime of intensive glucose control in indi-
vidual patients. At a group level, treating a larger proportion of
patients decreased the incidence of major vascular events and
increased the incidence of severe hypoglycaemia. However,
this is not informative of the risk to benefit ratio of intensive
glucose control at a patient-specific level. Despite shared risk
factors for both outcomes, they did vary in strength and pro-
duced variations in net estimated treatment effect for individual
patients. Further, we observed a different relationship between
baseline HbA1c level and risk of severe hypoglycaemia in pa-
tients assigned to standard treatment compared with intensive
treatment. In patients receiving intensive glucose control, the
risk of severe hypoglycaemia increased with higher levels of
HbA1c, whereas risk slightly decreased in patients receiving
standard therapy. A higher risk of hypoglycaemia in patients
with poorer glycaemic control was also demonstrated in the
ACCORD trial [31]. In ADVANCE, the increased risk was
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Fig. 3 Distribution of individual patient treatment effects of intensive glucose control for (a) 5 year ARR for major vascular events and (b) ARI for
severe hypoglycaemia, and net treatment effect assigning (c) half the weight or (d) similar weight to severe hypoglycaemia
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confined to the intensive treatment arm, probably representing
the use of more complex glucose-lowering strategies, including
more frequent use of insulin, in an attempt to achieve the lower
glycaemic target in this group.
Due to the combined and multiplicative effect of multiple
risk factors, no single characteristic could be used to identify
patients with a positive effect. Therefore, we developed a risk
score incorporating multiple patient-specific variables to tailor
the assessment of the risks and benefits of treatment for the
individual patient. For some patients, the benefits of intensive
glucose control will largely offset treatment disadvantages
(see Text box). On the other hand, for patients with a smaller
or absent net benefit of intensive treatment a less stringent
treatment target might be considered. Further, individual treat-
ment decisions are critically dependent on the relative
appraisal of beneficial and adverse treatment effects. The pres-
ent analysis indicated that the majority (85%) of patients in
ADVANCE derived a net benefit from intensive glucose con-
trol when positive and negative effects were assumed to be
equally important. However, the comparison of the immediate
risk of severe hypoglycaemia in terms of clinical importance
and relevance with, for example, the long-term prevention of
end stage renal disease is difficult for both patients and clini-
cians. Some patients are likely to attach greater weight to
avoiding severe hypoglycaemia in relation to, for example,
their occupation or the presence of hypoglycaemia unaware-
ness. At a group level, a selective treatment strategy aimed at
treating the 85% patient subgroup with an estimated net ben-
efit had no effect on the overall incidence of major vascular
events or severe hypoglycaemia. Thus, selective treatment
according to conflicting risks may benefit the individual pa-
tient while achieving similar population level effects com-
pared with treating everyone.
Importantly, we showed that intensive glucose control was
not associated with the risk of death from any cause. There
was a similar, albeit non-significant, relative risk reduction of
death with intensive treatment across different levels of esti-
mated mortality risk as evaluated by the continuous interac-
tion terms between treatment and risk [32, 33]. The interaction
of intensive treatment with HbA1c level on risk of death, as
reported in a post hoc analysis of the ACCORD trial, was not
significant in this study [34]. Hence, the present analyses did
not find any evidence of an excess risk of death with intensive
glucose control, not even for the potentially most vulnerable
patients who are at highest risk of death.
Some limitations need to be considered with respect to this
study; first, follow-up data under randomised therapies were
only available for amedian of 5.0 years, while treatment is often
lifelong. In addition, treatment targets for participants were
fixed at study enrolment whereas in clinical practice treatment
goals are often revised at repeated outpatient visits.
Nevertheless, in ADVANCE the intensive treatment target
was gradually reached over a period of 3 years. Hence, this
paper provides estimates of the individual benefits and harms
of adhering to a specific treatment target in the longer term.
Second, the present comparison used a composite outcome of
major beneficial effects, comprising individual components
with a potentially different clinical impact. However, clinical
usefulness and interpretation will benefit from such a summary
outcome of positive vascular effects. For example, the develop-
ment of macroalbuminuria might go unnoticed to a patient but
does confer a three to fivefold increased risk of (cardiovascular)
mortality [35]. Similarly, we focused on the main adverse effect
of treatment; effects on weight change were not incorporated,
yet earlier concerns about weight gain were largely refuted for
the gliclazide-based regimen used in ADVANCE [36]. Also,
mild hypoglycaemia (which can, for example, result in
avoiding exercise and increased worry about hypoglycaemia
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Fig. 4 Overall effects of selective intensive glucose control treatment on
the 5 year incidence of major vascular events and severe hypoglycaemia.
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85% of patients had an estimated positive individual net effect. The left y-
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with a positive estimated net benefit from the intervention group and
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that affects daily life) was not incorporated into this study since
it is not related to the risk of vascular events or death [11, 37,
38]. Third, the analyses and estimates related to this study apply
to those patients who were eligible for inclusion and were treat-
ed with a gliclazide-based regimen. At the end of follow-up the
most frequently prescribed drugs were gliclazide, metformin
and insulin. Although the use of sulfonylureas is decreasing,
they are firmly embedded in the current guidelines [30, 39].
Further, novel therapies such as incretin-based drugs and
sodium-glucose cotransporter-2 inhibitors may demonstrate
different safety profiles and result in different risk to benefit
ratios. Fourth, in the absence of available external risk algo-
rithms for the outcomes of interest, we derived new prediction
models that are likely to perform optimistically in the sample
fromwhich theywere derived [24]. Therefore, we evaluated the
amount of over-optimism and provided adjusted effect esti-
mates and performance measures. Finally, individual estimates
are accompanied by larger uncertainty margins. However, once
the causal effects of treatment have been established at a group
level, the point estimate is the most likely approximation of the
true effect for the individual patient and is most useful to inform
medical decisions.
In conclusion, the individual effects of intensive glucose
control in terms of reducing the risk of major vascular events
and increasing the risk of severe hypoglycaemia can be quan-
tified using a multivariable risk algorithm. The estimated net
benefit was positive in the majority of patients in the
ADVANCE trial, with the percentage benefiting depending
upon the individual weight assigned to the beneficial and ad-
verse effects of treatment.
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